人胰升糖素样肽1类似物利拉鲁肽减轻2型糖尿病患者体重的作用

Liraglutide, a human glucagon-like pepfide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes

肥胖与多种代谢异常相关，包括胰岛素抵抗和2型糖尿病。减轻体重能有效改善胰岛素敏感性，并由此降低肥胖相关的2型糖尿病和心血管疾病风险。研究证实，人胰升糖素样肽1（GLP-1）类似物利拉鲁肽不论单用还是与其他降糖药物联用，都可更好地控制血糖，保护胰岛β细胞功能，并通过抑制摄食和延缓胃肠蠕动减轻体重，这为2型糖尿病患者的治疗提供了新的选择。

Obesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesity- associated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 （ GLP-1 ） analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.